COV-pantent for digital patologi godkjent i USA. Endelig!
I går kom det en børsmelding fra COV om at pantentet for digital patologi for INIFY Prostate Screening er godkjent av The U.S. Patent and Trademark Office (USPTO). Dette er meget gode nyheter og viser at produktlanseringen kommer meget snart. Mest sannsynlig like før RSNA.
Glad for at jeg de siste 2-3 ukene har kjøpt ytterligere aksjer i COV og har flere aksjer enn noen gang de siste 4-5 årene.
ContextVision announces first digital pathology patent granted for its unique and objective data-generation method
STOCKHOLM – November 21, 2019 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, announce today that its proprietary Master Annotation method has received patent protection in the U.S.
The U.S. Patent and Trademark Office (USPTO) has granted a patent to ContextVision for this invention, titled “method and system for detecting pathological anomalies in a digital pathology image and method for annotating a tissue slide”.
ContextVision developed this method to automatically and more objectively outline specific structures in pathology images used for training deep learning algorithms. It identifies and highlights cancer areas and other structures by using multi-plex immunofluorescent staining. This enables development of algorithms based on objective data with high accuracy.
“This patent protection is a milestone for ContextVision, and I´m so happy and proud to see this idea become reality. Thanks to a strong team effort we have managed to implement the invention as a standard component in our product development,” said Kristian Eurén at ContextVision, inventor of the Master Annotation method and product manager.
The upcoming product, INIFY Prostate Screening, learns by using the patented Master Annotation method. INIFY Prostate Screening is a powerful AI-based software that outlines and quantifies suspected cancerous areas in a series of prostate biopsies. It pre-sorts slides in a worst-first order, allowing pathologists to get right to work on the most relevant areas. The product is currently in beta-test phase.
“This is a clear proof of the innovative capacity we have in our multidisciplinary team. We are dedicated to developing best-in-class decision support tools for highly accurate diagnosis and prognostication of cancer. The accuracy of the algorithms we develop depends strongly on what we feed into our neural networks,” said Fredrik Palm, ContextVision CEO. “Strengthened by this achievement, we continue with confidence towards the growing digital pathology market”.
Glad for at jeg de siste 2-3 ukene har kjøpt ytterligere aksjer i COV og har flere aksjer enn noen gang de siste 4-5 årene.
ContextVision announces first digital pathology patent granted for its unique and objective data-generation method
STOCKHOLM – November 21, 2019 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, announce today that its proprietary Master Annotation method has received patent protection in the U.S.
The U.S. Patent and Trademark Office (USPTO) has granted a patent to ContextVision for this invention, titled “method and system for detecting pathological anomalies in a digital pathology image and method for annotating a tissue slide”.
ContextVision developed this method to automatically and more objectively outline specific structures in pathology images used for training deep learning algorithms. It identifies and highlights cancer areas and other structures by using multi-plex immunofluorescent staining. This enables development of algorithms based on objective data with high accuracy.
“This patent protection is a milestone for ContextVision, and I´m so happy and proud to see this idea become reality. Thanks to a strong team effort we have managed to implement the invention as a standard component in our product development,” said Kristian Eurén at ContextVision, inventor of the Master Annotation method and product manager.
The upcoming product, INIFY Prostate Screening, learns by using the patented Master Annotation method. INIFY Prostate Screening is a powerful AI-based software that outlines and quantifies suspected cancerous areas in a series of prostate biopsies. It pre-sorts slides in a worst-first order, allowing pathologists to get right to work on the most relevant areas. The product is currently in beta-test phase.
“This is a clear proof of the innovative capacity we have in our multidisciplinary team. We are dedicated to developing best-in-class decision support tools for highly accurate diagnosis and prognostication of cancer. The accuracy of the algorithms we develop depends strongly on what we feed into our neural networks,” said Fredrik Palm, ContextVision CEO. “Strengthened by this achievement, we continue with confidence towards the growing digital pathology market”.
bulleye
19.12.2019 kl 17:23
1194
Det var en helt grei julepresang at COV gikk 5% i dag på det høyeste volumet på lang tid. Digital patologi skal lanseres i 2019, så da er det snakk om noen dager til meldingen kommer. Skal bli spennende å se om vi bryter toppen fra tidligere i høst på kr 105. Når dette skjer er det minimal motstand opp til ATH på kr. 155 fra 1997/1998. Det er ikke spørsmål om det skjer, men når.
utepils
19.12.2019 kl 17:04
1205
Godt med en dag med OK volum igjen. Stiger 5% på en omsetning vi ikke har sett på en stund. Spennende når det kommer noe nyheter om inntreden på det nye markedet
bulleye
02.12.2019 kl 12:52
1420
Endelig litt opptur i COV igjen. Bedre kjøperside enn på lenge og det er tydelig at noen vil inn i aksjen før oppgangen kommer ved lanseringen av digital patologi. I det siste har det ved 2 anledninger blitt omsatt poster på 25.000 aksjer i COV (ikke omsatt over OSE). Hvem det er som kjøper/selger får vi sannsynligvis vite når oppdatert aksjonæroversikt blir lagt ut på hjemmesiden om noen dager.
bulleye
29.11.2019 kl 11:46
1528
ContextVision – Arto Järvinen appointed as the new CTO
Stockholm – November 29, 2019 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, is pleased to announce that Arto Järvinen has been promoted to the company’s CTO position. Järvinen has been Director of R&D since 2011 and has been instrumental in leading the company’s operational R&D work. Järvinen has succeeded the former CTO and co-founder Martin Hedlund. Hedlund retired earlier this year but will resume in his board position for the company.
“We are very pleased that Arto Järvinen is the new CTO at ContextVision. The company is in a transformational period where artificial intelligence technology plays a key role, especially as we are in the process of expanding our business portfolio and entering into the digital pathology market. The CTO role is very important in this journey and I’m confident that Arto’s leadership, knowledge and experience will be extremely valuable for our company,” says ContextVision’s CEO Fredrik Palm.
”It has never been a more exciting time to be an engineer than now. Converging and exponential technologies make products only dreamt of ten years ago a reality today. My highest priority as the CTO of ContextVision is to make sure that ContextVision stays at the forefront of innovation by managing a portfolio of cutting-edge research projects,” says Järvinen.
“Martin Hedlund is one of the founders of ContextVision, he has spent his carrier building and developing the company. His entrepreneurial mindset combined with technical know-how and experience has been instrumental in making ContextVision a leader in image enhancement and analysis. In addition, he has played a key role in the adoption of AI-technology within the company to prepare for further growth. We truly want to thank Martin for all these years,” says Palm.
Stockholm – November 29, 2019 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, is pleased to announce that Arto Järvinen has been promoted to the company’s CTO position. Järvinen has been Director of R&D since 2011 and has been instrumental in leading the company’s operational R&D work. Järvinen has succeeded the former CTO and co-founder Martin Hedlund. Hedlund retired earlier this year but will resume in his board position for the company.
“We are very pleased that Arto Järvinen is the new CTO at ContextVision. The company is in a transformational period where artificial intelligence technology plays a key role, especially as we are in the process of expanding our business portfolio and entering into the digital pathology market. The CTO role is very important in this journey and I’m confident that Arto’s leadership, knowledge and experience will be extremely valuable for our company,” says ContextVision’s CEO Fredrik Palm.
”It has never been a more exciting time to be an engineer than now. Converging and exponential technologies make products only dreamt of ten years ago a reality today. My highest priority as the CTO of ContextVision is to make sure that ContextVision stays at the forefront of innovation by managing a portfolio of cutting-edge research projects,” says Järvinen.
“Martin Hedlund is one of the founders of ContextVision, he has spent his carrier building and developing the company. His entrepreneurial mindset combined with technical know-how and experience has been instrumental in making ContextVision a leader in image enhancement and analysis. In addition, he has played a key role in the adoption of AI-technology within the company to prepare for further growth. We truly want to thank Martin for all these years,” says Palm.
bulleye
25.11.2019 kl 08:44
1672
COV ble i dagens Finansavis (side 26) trukket frem som det mest opplagte AI selskapet på Oslo Børs. Microsoft og Google, samt flere andre store selskaper er på oppkjøpsjakt på selskaper innen AI.
AI-muligheter på børs
Analyseselskapene venter enorm etterspørsel etter AI-teknologi. En lang rekke selskaper på børs har posisjonert seg for et multimilliardmarked i voldsom vekst.
Et av de mest opplagte AI-selskapene på Oslo Børs er Contextvision, som har spesialisert seg på bildeanalyse og kunstig intelligens.
I 2014 tok selskapet en strategisk beslutning om å satse på AI og dyp læring (deep learning).
Dyp læring er en læreprosess som handler om å trene opp såkalte dype, kunstige, nevrale nettverk. Mens maskinlæring er algoritmer som gjør datamaskiner i stand å lære fra og utvikle atferd basert på empiriske data, er dyp læring en prosess hvor datamaskiner lærer om noe de ikke vet eller kan fra før.
Contextvision endte opp med et forskingsprosjekt for digital patologi, som igjen ble et eget forretningsområde i 2018. Teknologien skal først og fremst være et hjelpemiddel for patologene, så de ikke overser kreftområder, samt redusere tiden det tar å undersøke pasientene.
Selskapet har tidligere sagt at algoritmen er blitt testet mot uavhengige patologer på biopsier fra prostata. Testen viste av algoritmen markerte mistenkelig kreft som ikke patologene så.
AI-muligheter på børs
Analyseselskapene venter enorm etterspørsel etter AI-teknologi. En lang rekke selskaper på børs har posisjonert seg for et multimilliardmarked i voldsom vekst.
Et av de mest opplagte AI-selskapene på Oslo Børs er Contextvision, som har spesialisert seg på bildeanalyse og kunstig intelligens.
I 2014 tok selskapet en strategisk beslutning om å satse på AI og dyp læring (deep learning).
Dyp læring er en læreprosess som handler om å trene opp såkalte dype, kunstige, nevrale nettverk. Mens maskinlæring er algoritmer som gjør datamaskiner i stand å lære fra og utvikle atferd basert på empiriske data, er dyp læring en prosess hvor datamaskiner lærer om noe de ikke vet eller kan fra før.
Contextvision endte opp med et forskingsprosjekt for digital patologi, som igjen ble et eget forretningsområde i 2018. Teknologien skal først og fremst være et hjelpemiddel for patologene, så de ikke overser kreftområder, samt redusere tiden det tar å undersøke pasientene.
Selskapet har tidligere sagt at algoritmen er blitt testet mot uavhengige patologer på biopsier fra prostata. Testen viste av algoritmen markerte mistenkelig kreft som ikke patologene så.
bulleye
22.11.2019 kl 10:19
1815
Synes det er merkelig at COV ikke reagerer mer enn den gjør på den meget positive børsmeldingen som kom i går. Nå ligger alt klart for at COV skal være de første som kommer inn på et marked som utgjør ca. 1,8 milliarder og et marked som vokser i rekordfart. Dvs. et marked som er 10 ganger større enn det markedet (bildeforbedring) som selskapet har en markedsandel på ca. 50%. En markedsandel på 10% av digital patologi vil øke omsetningen fra ca. 100 mill. til ca. 300 mill. uten at kostnadene øker nevneverdig. Det er denne skalerbarheten som gjør COV unik. Ofte at COV reagerer først 1-2 dager etter en positiv melding, så vi får vente å se.
Redigert 22.11.2019 kl 13:59
Du må logge inn for å svare